Related Experiment Video
Updated: Apr 22, 2026

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
Accounting for Differences in Plasma Protein Binding between Fish and Humans for Supporting Environmental Risk
A Ross Brown1, Maciej Trznadel1, Siffreya Pedersen1
1Biosciences, Faculty of Health and Life Sciences, University of Exeter, Stocker Road, Exeter, Devon EX4 4QD, United Kingdom.
Abstract:
The Fish Plasma Model (FPM) predicts steady-state concentrations of active pharmaceutical ingredients (APIs) in fish blood plasma based on partitioning from the surrounding (water) environment. Total plasma concentration is then compared to the human therapeutic concentration to indicate environmental risk, assuming that human pharmaceutical targets are conserved in fish. However, only the unbound fraction (fu) of API is available for pharmacological action and plasma protein binding, and the binding of APIs may differ between species. We quantify fu for 44 APIs with wide ranging physicochemical properties in three fish species: a salmonid, rainbow trout (Oncorhynchus mykiss) and two cyprinids, fathead minnow (Pimephales promelas), and koi carp (Cyprinus rubrofuscus), and draw comparisons with fu in humans. We examine interspecies differences in fu in relation to blood physicochemistry and protein and lipid composition. We show that anionic APIs often exhibit substantially (×10) higher fu in fish compared with humans, and this was most apparent in rainbow trout, despite this species possessing protein(s) orthologous to human serum albumin, a major binding protein for anionic APIs in humans. We recommend accounting for fu in fish versus humans and using rainbow trout as a conservative species in the FPM for modeling API availability and effects in fish.
Related Concept Videos
Drug Distribution: Plasma Protein Binding
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...

